Australia's largest stock trading and investment forum Australia's #1 stock forum

RAC

Click for more information

0.60%

$1.69 race oncology ltd

Ann: Updated Strategy and Investor Presentation, page-467

First 467 Last

Share
Profile

Follow
IndexInvestor

8,516 Posts.

1397

07/12/23

08:07

Post #: 71315944
Share

Originally posted by Davisite: ↑

The small anticancer efficacy is only required to get RC220 out of the supportive care category and allow doctors to use it without having to fight with the insurance companies for hours on the phone getting prior authorisation. As long as the label says anticancer then it doesn’t matter how small the anticancer efficacy - this was for me the most surprising aspect of the Triangle report.

In the long term doctors will likely either reduce the dose of anthracycline they use and increase the amount of RC220 and/or increase the number of treatment cycles. Both of these will make RC220 much more effective as an anticancer agent.

Of course we should not forget m6A here which is a totally independent pathway to anticancer efficacy.

Expand

Thanks for your detailed answers to the complex question.

You lost me at the end when you mentioned the "independent" m6A pathway.
Wouldn't any observed anticancer efficacy at the low to moderate bisantrene doses which will be used be MAINLY due to FTO inhibition rather than to Topo2?

RAC Price at posting: 87.0¢ Sentiment: Hold Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

NEC

Nine Entertainment announces its CEO is stepping down – on an ex-divvy day

BRX

Belararox to grow copper footprint in Botswana with 4,286 square km tenure

CU6

Clarity progresses SECuRE trial with positive safety results

3 stocks with antimony news on Thursday

CHN

Chalice jumps on Putin nickel export ban threat – but then there's bad news

DXB

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3

MTM

Forget gallium: MTM says it's extracted gold from e-waste

ASX Market Open: Local bourse to trade green | Thursday September 12

SS1

Sun Silver confirms high-grade extension theory at Maverick Springs with 79.6 g/t intercept

GTR

GTI extends uranium mineralisation at Lo Hema through development drilling

There are more pages in this discussion • 42 more messages in this thread...

First 467 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.69		Change 0.010(0.60%)		Mkt cap ! $287.1M

Open	High	Low	Value	Volume
$1.69	$1.70	$1.65	$89.01K	53.2K

Buyers (Bids)

No.	Vol.	Price($)
1	2342	$1.69

Sellers (Offers)

Price($)	Vol.	No.
$1.70	5	1

View Market Depth

No.	Vol.	Price($)
1	2342	1.685
1	3664	1.680
1	5077	1.660
2	1805	1.650
1	612	1.635

Price($)	Vol.	No.
1.695	5	1
1.700	11000	1
1.730	2399	1
1.750	952	2
1.775	1328	1

Last trade - 16.10pm 13/09/2024 (20 minute delay)

RAC (ASX) Chart

SPONSORED BY